Advanced echocardiographic techniques

Abstract
Echocardiography has advanced significantly since its first clinical use. The move towards more accurate imaging and quantification has driven this advancement. In this review, we will briefly focus on three distinct but important recent advances, three-dimensional (3D) echocardiography, contrast echocardiography and myocardial tissue imaging. The basic principles of these techniques will be discussed as well as current and future clinical applications.

Keywords: contrast imaging, echocardiography, myocardial tissue imaging, ventricular assessment.

3D echocardiography
The heart is a complex, moving, 3D shape and for many years operators of ultrasound have had to build up an image of the heart in their mind using a series of two-dimensional (2D) “cuts”. Live 3D echocardiography is a novel technique for evaluation of cardiac abnormalities without any of the assumptions made in 2D imaging. Recent guidelines on the acquisition and display of 3D datasets have been published to attempt to standardise the clinical application of this advanced echocardiographic modality.¹

A 2D phased array transducer provides only one plane of imaging at a time whereas a 3D matrix array transducer functions in a similar way to a shower head, giving a 3D “shower” of ultrasound in both the lateral and elevation planes. The 2D imaging plane within the 3D dataset may therefore be “foreshortened” as the LV apex is captured within the data set. Post processing adjustments can then be made to obtain the true apex (Figures 1 and 2) allowing for more accurate assessment of LV volumes and ejection fraction.

There are two types of 3D imaging:

i) live 3D where a single beat volume can be acquired

ii) multi-beat 3D, where the 3D dataset is acquired over multiple beats (usually from 2 to 7 beats). The advantage of a live 3D volume is that there is no “stitching” of beats together which may cause artifacts and misalignment of structures. In addition, single beat volume can be used in...
the presence of arrhythmias such as atrial fibrillation which are common in the cardiac patient population. The downside is that the spatial and temporal resolution is compromised and can reduce accuracy in quantification. A multi-beat acquisition gives a much higher frame rate and is often the only type of 3D dataset that can be analysed in dedicated 3D quantification software packages. Despite these limitations, 3D echocardiography has significant advantages over cardiac magnetic resonance imaging (MRI) and computed tomography (CT) in that it is relatively inexpensive, portable and can be used for patients with metal implants and claustrophobia.

**Left ventricular assessment**

Left ventricular mass, volumes and ejection fraction (EF) are important prognostic parameters that are used for serial follow up of patients in various conditions including congestive cardiac failure, ischaemic heart disease, and valvular disease and for monitoring chemotherapy cardiac toxicity. Unfortunately, 2D echocardiography has limited test-retest reliability with regards to measuring LV parameters and has been reported to give a variation in EF between operators of as much as 11%. Cardiac MRI is considered the gold standard as it overcomes the geometrical assumptions made in 2D echocardiography; however the cost and availability of MRI makes it more difficult in a clinical setting. 3D echocardiography has a lower cost than MRI and has been found to have a high reproducibility in regards to LV volumes, EF and mass and is comparable to MRI. There is a high test-retest reliability of 3D LV volume and EF measurements making it ideal for serial EF follow up, particularly when using a semi-automated border detection software which does not rely on geometric assumptions of a “normal” LV. It also improves the detection of regional wall motion abnormalities compared with 2D imaging. Contrast imaging (discussed later) can also be used with 3D echocardiography to improve image quality and assist in assessment of EF and regional wall motion abnormalities.

Recently, 3D echocardiography has been used to determine LV dyssynchrony. It has been found that a 3D derived dyssynchrony index can determine which chronic heart failure patients are more likely to respond to cardiac resynchronisation therapy. Contraction wave mapping is also thought to assist in determining the area of latest activation and therefore the optimal position for lead placement.

3D echocardiography may also be used in the assessment of right ventricular and left atrial volumes and function but is beyond the scope of this review.

**Valvular assessment:**

As a 3D dataset can be cropped and displayed in any orientation, direct visualisation or “enface” views can be obtained (depending on image quality) of all four valves. The development of 3D transoesophageal echocardiography (TOE) has made 3D valvular assessment easier with superior resolution of images, particularly in mitral valve disease. The ability to display the mitral valve enface and in a surgical view (displayed as the surgeon would see the valve after opening up the left atrium) allows easier communication between cardiology and surgical teams (Figures 3 and 4). Note the resolution differences between the transthoracic (TTE) and TOE images.

Both 3D TOE and TTE have been shown to improve the detection of mitral valve disease, particularly where complex pathology such as a cleft or prolapse at the commissural level
The measurement of mitral valve area in mitral stenosis from 3D planimetry has a better correlation with invasively derived results than 2D alone\(^{55-62}\) (Figure 5).

Other cardiac valves can also be visualised and assessed using both 3D TTE and TOE. Estimation of aortic valve area in aortic stenosis via direct planimetry\(^{63-66}\) and continuity equation\(^{67,68}\) can be performed using 3D and has been shown to be superior to 2D assessment alone.

Colour Doppler is also available using 3D\(^{69,70}\) however single beat acquisition is not available in this mode due to poor temporal and spatial resolution. A 4 to 7 beat acquisition is required to obtain a 3D colour dataset and care must be taken to avoid “stitching” artifact. Quantification of both the vena contracta and the proximal isovelocity surface area (PISA) in mitral regurgitation has been shown to be more accurate and reproducible using 3D compared to 2D\(^{71-74}\). The vena contracta in the assessment of aortic regurgitation can also be more accurately assessed with 3D echocardiography\(^{75,76}\).
Advanced echocardiographic techniques

Other 3D uses

The same measurement package used for calculation of mitral valve area may also be used to size atrial septal defects prior to device closure and has been shown to be superior to 2D assessment alone.\(^7\) (Figure 6).

Another less heralded but very clinically useful feature of 3D technology is multi-plane imaging which allows a structure to be displayed in simultaneous orthogonal views. Not only does this make interrogation of structures such as mitral valve and left atrial appendage quicker and more accurate, it plays an important role in guiding interventions such as septal punctures (Figure 7), septal defect closure devices (Figure 8).\(^78\)–\(^80\) Percutaneous

---

Figure 5: A 3D biplane transthoracic image of mitral valve stenosis demonstrating the line of measurement through the mitral valve on the parasternal long axis view (left pane) with the measurement of the mitral valve area on the right pane. AoV – aortic valve, MV – mitral valve.

Figure 6: A 3D transoesophageal image of an atrial septal defect viewed from the left atrial aspect. ASD – atrial septal defect, AoV – aortic valve, SVC – superior vena cava.
valve repairs,\textsuperscript{81} percutaneous repair of prosthetic mitral valve paravalvular regurgitation,\textsuperscript{82–85} balloon valvuloplasty\textsuperscript{81} and placement of left atrial appendage occluder devices.\textsuperscript{86}

Contrast echocardiography
Contrast echocardiography is an important arsenal in any echo laboratory in improving image quality. Its uptake into the Australian setting has been slow but has gained momentum since the introduction of second generation contrast agents. This technique has special relevance in Australia with increasing obesity and co-morbidities such as airway diseases making optimal imaging difficult in up to 10–15\% of patients.\textsuperscript{87}

Contrast echo relies on different ultrasound properties exhibited by the contrast agents and human tissue enabling better delineation of the endocardium. Agitated saline injected into peripheral veins has long been used as a simple and readily available contrast agent to opacify right heart structures as well as identify intracardiac shunts and improve Doppler signals (i.e. tricuspid regurgitation). However, left heart contrast agents require that the microbubbles are small (4–5 μm) and
Figure 9: An apical 4 chamber view of the left ventricle without contrast – note that the lateral wall is poorly visualised. LV – left ventricle.

Figure 10: The same image as Figure 8 with the addition of contrast – note the improvement of lateral wall endocardial/ cavity border definition. LV – left ventricle.
Figure 11: A contrast image demonstrating an apical thrombus (seen as black against the white contrast). LV – left ventricle.

Figure 12: A contrast image demonstrating apical hypertrophy – note the degree of left ventricular cavity obliteration (arrow).
resilient enough to pass through the pulmonary circulation. Commercially available contrast agents are small microbubbles consisting of an inert gas encapsulated by a surface shell, often a lipid or polymer coat. When subjugated to ultrasound waves they oscillate (normal tissues don’t), creating multiple frequencies that can create a stronger signal intensity in comparison to tissue which causes the blood pool to opacify hence improving endocardial definition. Furthermore, current ultrasound machines use various processes to suppress tissue signals while enhancing the signal from the contrast agents.

**Contrast safety**

The Food and Drug Administration (FDA) and European licensing authority in the recent past have raised safety concerns based on a higher than usual incidence of deaths in critically ill patients who have undergone contrast echo. However, subsequent studies using a larger numbers of patients have demonstrated conclusively that contrast is very safe. The half life of contrast echo is short and it is excreted from the body through the lungs within a few minutes. Unlike other contrast agents used in imaging, echo contrast does not affect the kidneys and has a very low incidence of allergic reactions. The most common side-effects that patient may experience are minor and include flushing headache, nausea, chest or back pain. The only absolute contra-indication to contrast would include previous allergy to the agent and known intra-cardiac shunting.7

**Administration of contrast**

All major ultrasound companies have a contrast package that can be purchased as an option. The mechanical index (the power of the ultrasound beam) needs to be reduced to avoid destroying the microbubbles and the focal zone should be lowered to the base of the heart (around the mitral valve level). The near field gain needs to be reduced as the contrast is particularly bright in the LV apex. The contrast agent is injected into a peripheral vein very slowly along with a saline flush or for sustained imaging. An infusion pump may be used. Any remaining contrast is discarded. The agents have a six-month shelf life and needs to be refrigerated. The current American Society of Echocardiography (ASE) and European Association of Echocardiography (EAE) guidelines suggest that the use of contrast agents are indicated when greater than two of the 17 LV wall segments are poorly visualised (Figures 9 and 10). Currently there are no specific Australian guidelines available on the use of contrast agents in echocardiography.

If there is not enough contrast in the LV (noted as contrast “swirling” in the LV) you can either inject more contrast or reduce the mechanical index. If attenuation of the beam occurs you usually have to wait for some of the contrast to leave the LV or increase your mechanical index.

**Clinical indications**

The most common use of contrast is to better assess LV function in patients whose images are suboptimal with normal harmonic imaging, known as LV opacification (LVO). It can also be used for stress and dobutamine echocardiography to increase the number of wall segments visualised enabling greater accuracy in diagnosing coronary artery disease. It is also particularly useful in assessing for apical thrombus which appears black in comparison to the white blood pool (Figure 11). Rare conditions such as apical hypertrophy can be distinguished from foreshortening using contrast (Figure 12). Non-compaction cardiomyopathy which is characterised by deep recesses within the endocardium can also be highlighted.

---

**Figure 13:** Tissue Doppler imaging demonstrating velocity curves. The peak systolic velocity is labeled as $s'$, the peak early diastolic velocity is labeled as $e'$ and the atrial kick diastolic velocity is labeled as $a'$. 

---

![Figure 13: Tissue Doppler imaging demonstrating velocity curves. The peak systolic velocity is labeled as $s'$, the peak early diastolic velocity is labeled as $e'$ and the atrial kick diastolic velocity is labeled as $a'$.]
by contrast echo. Contrast can also be used to enhance the quality of Doppler signals and is particularly useful in difficult aortic stenosis cases. Assessment of myocardial perfusion can also be performed but its use for this purpose has not yet been approved by the FDA and therefore is still in the research and development phase.

Myocardial tissue Imaging

One of the newer and exciting advances in echocardiography is the ability to use imaging techniques which are based on tissue Doppler or myocardial speckles to directly assess LV function and mechanics. These techniques unlike EF and visual estimation of LV function, which look at volume displacement, directly assess the mechanics of the myocardial tissue. They can measure the velocity of myocardial motion or the deformation (also known as strain). This technique is more commonly used to assess mitral annular velocities to assist in the determination of diastolic function. Tissue Doppler imaging (TDI) uses the same principle as pulsed wave Doppler except that it detects myocardial motion in relationship to the transducer rather than blood flow (Figure 13). The best profile is obtained when the motion of the tissue is directly aligned to the ultrasound beam. Hence TDI is best suited for myocardial motion in the longitudinal plane using an apical window. This angle dependency of TDI is this techniques' greatest limitation. Strain or myocardial deformation differs from myocardial velocity in that it is not affected by tethering, i.e. being pulled along or affected by other myocardial segments (discussed later). Strain using TDI is more accurate in assessing regional wall motion than myocardial velocity alone.

TDI velocity data has been used extensively for the detection of mechanical dyssynchrony with excellent results in predicting response to cardiac resynchronisation therapy in single centres with proficiency in this technique; however a recent multicentre trial (PROSPECT) using TDI dyssynchrony analysis has disappointing results indicating that this technique was subjective and needed expertise in image analysis. Speckle tracking strain
Figure 16: A tissue Doppler graph with 3 myocardial sample volumes on the septal wall. The yellow sample volume is the most basal point with the red sample volume the most apical point. The corresponding graphs demonstrate a higher velocity in systole of the more basal myocardial point (yellow arrow) than the more apical point (red arrow).

Figure 17: An apical 4ch view with 2 myocardial points highlighted and enlarged to demonstrate the unique speckle “fingerprint” at each point.
detection of dyssynchrony may overcome some of these reliability issues but this is yet to be verified on a larger scale.\textsuperscript{114–117}

The key differences between tissue velocity, strain and strain rate are illustrated in Figure 14. There are two myocardial “muscle bundles” shown in red (1) and green (2). In a normal heart the base of the heart descends to the apex during systole. The more basal muscle bundle (green) is pulled along by the more apical myocardium and therefore has a velocity even without contracting; however this green muscle bundle also has its own intrinsic contraction.

Because of this intrinsic contraction the velocity of the green muscle bundle is higher than that of the more apical red muscle bundle. To further illustrate this Figure 15 shows a heart with myocardial damage in the green muscle bundle. You can see that this damaged muscle bundle still has a velocity (this movement is known as tethering) however it is the same as the more apical red muscle bundle – indicating that there is no intrinsic contraction.

This velocity gradient from the base to the apex is how strain and strain rate are calculated from TDI data (Figure 16). Strain is calculated from the TDI data by comparing the velocity of two myocardial points and normalising this to the distance between these two points. Strain rate is simply the rate at which these two points move towards or away from each other.\textsuperscript{118}

Speckle tracking like tissue Doppler techniques also assess myocardial velocities and strain. This technique relies on tracking unique speckles found within the ultrasound image accentuated by harmonic imaging. These speckles are like unique fingerprints that can be tracked using complex algorithms to determine myocardial velocities or strain\textsuperscript{119–122} (Figure 17). However unlike Doppler techniques, they are angle independent and hence are not restricted to assess longitudinal function but can also assess circumferential and radial motion as well as rotation and twist of the myocardium (Figure 18). Speckle tracking requires high quality imaging with good spatial resolution so that the speckles are able to be tracked. The deformation (or strain) within the speckle fingerprint can be assessed directly rather than be converted from velocity information as the TDI technique does.\textsuperscript{119–122}

Strain imaging using both TDI and speckle tracking has been shown to be of benefit in patients with ischaemic heart disease for detection of regional wall motion abnormalities\textsuperscript{123–127} and in the detection of myocardial viability.\textsuperscript{128,129} Strain imaging has been shown to detect subclinical changes in patients with hypertrophic cardiomyopathy,\textsuperscript{130–134} amyloid heart disease,\textsuperscript{135–138} chemotherapy cardiac toxicity\textsuperscript{139} and may also assist in timing of surgery in valvular heart disease by detecting subtle changes prior to any decrease in ejection fraction (Figure 19).\textsuperscript{140–146}

**Figure 18:** The three directions of myocardial strain as measured by echocardiography. Panel A shows longitudinal strain, with positive strain as a lengthening of the myocardium (L1), zero strain as no change (L2) and negative strain as a shortening of the myocardium (L3). Panel B shows radial strain, with negative strain as a thinning of the myocardium (L1), zero strain as no change (L2) and positive strain as a thickening of the myocardium (L3). Panel C shows circumferential strain, with positive strain as a lengthening of the myocardial circle, zero strain as no change and negative strain as a shortening of the myocardial circle.
Conclusions
Though these new and evolving techniques are very different, they have a common purpose which is to improve the diagnostic, prognostic and therapeutic utility of echo in patients with cardiac disease. While competing imaging modalities such as cardiac MRI and CT have made rapid progress, echocardiography particularly with these new techniques still remains the primary imaging modality in cardiology. 3D imaging for LV volumes and EF and contrast imaging in difficult patients have become standard practice in many echocardiography labs and continue to assist in daily clinical practice. Myocardial image with strain and strain rate however still remains within the realm of research at this stage but holds significant future promise.

References
1. Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T, et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. *J Am Soc Echocardiogr* 2012; 25: 3–46.
2. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. *Circulation* 2003; 108: 977–82.
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991; 325: 293–302.
4. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. *J Am Coll Cardiol* 1986; 7: 729–42.
5. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). *Circulation* 1983; 68: 785–95.
6. Boucher CA, Bingham JB, Osbaken MD, Okada RD, Strauss HW, Block PC, et al. Early changes in left ventricular size and function after correction of left ventricular volume overload. *Am J Cardiol* 1981; 47: 991–1004.
7. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. *Am J Hypertens* 1995; 8: 221–28.
8. Gopal AS, Shen Z, Sapin PM, Keller AM, Schnellbaecher MJ, Leibowitz DW, et al. Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods. *Circulation* 1995; 92: 842–53.
9. Caiani EG, Corsi C, Sugeng L, MacEnaney JF, Weinert L, Mor-Avi V, et al. Improved quantification of left ventricular mass based on endocardial and epicardial surface detection with real time three dimensional echocardiography. *Heart* 2006; 92: 213–19.
10. Mor-Avi V, Jenkins C, Kuhl HP, Nesser HJ, Marwick T, Franke A, et al. Real-time 3-dimensional echocardiographic quantification of left ventricular volumes: multicenter study for validation with magnetic resonance imaging and investigation of sources of error. *JACC Cardiovasc Imaging* 2008; 1: 413–23.
11. Qin JX, Jones M, Shiota T, Greenberg NL, Tsujino H, Firstenberg MS, et al. Validation of real-time three-dimensional echocardiography for quantifying left ventricular volumes in the presence of a left ventricular aneurysm: in vitro and in vivo studies. *J Am Coll Cardiol* 2000; 36: 900–07.
12. Arai K, Hozumi T, Matsumura Y, Sugioka K, Takemoto Y, Yamagishi H, et al. Accuracy of measurement of left ventricular volume and ejection fraction by new real-time three-dimensional echocardiography in patients with wall motion abnormalities secondary to myocardial infarction. *Am J Cardiol* 2004; 94: 552–58.
13. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular...
parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004; 44: 878–86.
14 Nikitin NP, Constantini C, Loh PH, Ghosh J, Lukashchuk EI, Bennett A, et al. New generation 3-dimensional echocardiography for left ventricular volumetric and functional measurements: comparison with cardiac magnetic resonance. Eur J Echocardiogr 2006; 7: 365–72.
15 Tighe DA, Rosetti M, Vinch CS, Chandok D, Muldoon D, Wiggan B, et al. Influence of image quality on the accuracy of real time three-dimensional echocardiography to measure left ventricular volumes in unselected patients: a comparison with gated-SPECT imaging. Echocardiography 2007; 24: 1073–80.
16 Jacobs LD, Salgo IS, Goonewardena S, Weinert L, Coon P, Bardo D, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 2006; 27: 460–68.
17 Mor-Avi V, Sugeng L, Weinert L, MacEneaney P, Caiani EG, Koch R, et al. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation 2004; 110: 1814–18.
18 Yap SC, van Geuns RJ, Nemes A, Meijboom FJ, McGhie JS, Geleijnse ML, et al. Rapid and accurate measurement of LV mass by biplane real-time 3D echocardiography in patients with concentric LV hypertrophy: comparison to CMR. Eur J Echocardiogr 2008; 9: 255–60.
19 van den Bosch AE, Robbers-Visser D, Krenning BJ, McGhie JS, Helbing WA, Meijboom FJ, et al. Comparison of real-time three-dimensional echocardiography to magnetic resonance imaging for assessment of left ventricular mass. Am J Cardiol 2006; 97: 113–17.
20 Muraru D, Badano LP, Piccoli G, Gianfagna P, Del Mestre L, Ermacora D, et al. Validation of a novel automated border-detection algorithm for rapid and accurate quantitation of left ventricular volumes based on three-dimensional echocardiography. Eur J Echocardiogr 2010; 11: 359–68.
21 Soliman OI, Kirschbaum SW, van Dalen BM, van der Zwaan HB, Madhavian Delavary B, Vletter WB, et al. Accuracy and reproducibility of quantitation of left ventricular function by real-time three-dimensional echocardiography versus cardiac magnetic resonance. Am J Cardiol 2008; 102: 778–83.
22 Jenkins C, Chan J, Hanekom L, Marwick TH. Accuracy and feasibility of online 3-dimensional echocardiography for measurement of left ventricular parameters. J Am Soc Echocardiogr 2006; 19: 1119–28.
23 Bicudo LS, Tsutsui JM, Shiozaki A, Rochitte CE, Arteaga E, Mad C, et al. Value of real time three-dimensional echocardiography in patients with hypertrophic cardiomyopathy: comparison with two-dimensional echocardiography and magnetic resonance imaging. Echocardiography 2008; 25: 717–26.
24 Qin JX, Jones M, Travaglini A, Song JM, Li J, White RD, et al. The accuracy of left ventricular mass determined by real-time three-dimensional echocardiography in chronic animal and clinical studies: a comparison with postmortem examination and magnetic resonance imaging. J Am Soc Echocardiogr 2005; 18: 1037–43.
25 Oe H, Hozumi T, Arai K, Matsumura Y, Negishi K, Sugioaka K, et al. Comparison of accurate measurement of left ventricular mass in patients with hypertrophied hearts by real-time three-dimensional echocardiography versus magnetic resonance imaging. Am J Cardiol 2005; 95: 1263–67.
26 Jenkins C, Brinknell K, Chan J, Hanekom L, Marwick TH. Comparison of two- and three-dimensional echocardiography with sequential magnetic resonance imaging for evaluating left ventricular volume and ejection fraction over time in patients with healed myocardial infarction. Am J Cardiol 2007; 99: 300–6.
27 Pouleur AC, le Polain de Waroux JB, Pasquet A, Gerber BL, Gerard O, Allain P, et al. Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: comparison against cine magnetic resonance imaging. Heart 2008; 94: 1050–57.
28 Soliman OI, Krenning BJ, Geleijnse ML, Nemes A, Bosch JG, van Geuns RJ, et al. Quantification of left ventricular volumes and function in patients with cardiomyopathies by real-time three-dimensional echocardiography: a head-to-head comparison between two different semiautomated endocardial border detection algorithms. J Am Soc Echocardiogr 2007; 20: 1042–49.
29 Jochim Nesser H, Sugeng L, Corsi C, Weinert L, Niel J, Ebner C, et al. Volumetric analysis of regional left ventricular function with real-time three-dimensional echocardiography: validation by magnetic resonance and clinical utility testing. Heart 2007; 93: 572–78.
30 Corsi C, Coon P, Goonewardena S, Weinert L, Sugeng L, Polonsky TS, et al. Quantification of regional left ventricular wall motion from real-time three-dimensional echocardiography in patients with poor acoustic windows: effects of contrast enhancement tested against cardiac magnetic resonance. J Am Soc Echocardiogr 2006; 19: 886–93.
31 Marsan NA, Bleeker GB, Ypenburg C, Ghio S, van de Veire NR, Holman ER, et al. Real-time three-dimensional echocardiography permits quantification of left ventricular mechanical dyssynchrony and predicts acute response to cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2008; 19: 392–99.
32 Gorcsan J 3rd, Abraham T, Agler DA, Bax JJ, Derumeaux G, Grimm RA, et al. Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting— a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 2008; 21: 191–213.
33 Marsan NA, Bleeker GB, Ypenburg C, Van Bommel RJ, Ghio S, Van de Veire NR, et al. Real-time three-dimensional echocardiography as a novel approach to assess left ventricular and left atrium reverse remodeling and to predict response to cardiac resynchronization therapy. Heart Rhythm 2008; 5: 1257–64.
34 Kleijn SA, van Dijk J, de Cock CC, Allaart CP, van Rossum AC, Kamp O. Assessment of intraventricular mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy: comparison between tissue Doppler imaging and real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2009; 22: 1047–54.
35 Soliman OI, Geleijnse ML, Theuns DA, van Dalen BM, Vletter WB, Jordaeens LJ, et al. Usefulness of left ventricular systolic dyssynchrony by real-time three-dimensional echocardiography to predict long-term response to cardiac resynchronization therapy. Am J Cardiol 2009; 103: 1586–91.
36 Kapetanakis S, Kearney MT, Siva A, Gall N, Cooxan M, Monaghan MJ. Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 2005; 112: 992–1000.
37 Burgess MI, Jenkins C, Chan J, Marwick TH. Measurement of left ventricular dyssynchrony in patients with ischaemic cardiomyopathy: a comparison of real-time three-dimensional and tissue Doppler echocardiography. Heart 2007; 93: 1191–96.
38 Becker M, Hoffmann R, Schmitz F, Hundemer A, Kuhl H, Schauerte P, et al. Relation of optimal lead positioning as defined by three-dimensional echocardiography to long-term benefit of cardiac resynchronization. Am J Cardiol 2007; 100: 1671–76.
39 Gopal AS, Chukwu EO, Iwuchukwu CJ, Katz AS, Toole RS, Schapiro W, et al. Normal values of right ventricular size and function by real-time 3-dimensional echocardiography: comparison with
cardiac magnetic resonance imaging. *J Am Soc Echocardiogr* 2007; 20: 445–55.

40 Jenkins C, Chan J, Bricknell K, Strudwick M, Marwick TH. Reproducibility of right ventricular volumes and ejection fraction using real-time three-dimensional echocardiography: comparison with cardiac MRI. *Chest* 2007; 131: 1844–51.

41 Niemann PS, Pinho L, Balbach T, Galuschký C, Blankenhagen M, Silberbach M, *et al*. Anatomically oriented right ventricular volume measurements with dynamic three-dimensional echocardiography validated by 3-Tesla magnetic resonance imaging. *J Am Coll Cardiol* 2007; 50: 1668–76.

42 Sugeng L, Mor-Avi V, Weinert L, Niel J, Ebner C, Steringer-Mascherbauer R, *et al*. Multimodality comparison of quantitative volumetric analysis of the right ventricle. *JACC Cardiovasc Imaging* 2010; 3: 10–18.

43 Kjaergaard J, Petersen CL, Kjaer A, Schaadt BK, Oh JK, Hassager C. Evaluation of right ventricular volume and function by 2D and 3D echocardiography compared to MRI. *Eur J Echocardiogr* 2006; 7: 430–38.

44 Marsan NA, Tops LF, Holman ER, Van de Veire NR, Zeppenfeld K, Boersma E, *et al*. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. *Am J Cardiol* 2008; 102: 847–53.

45 Anwar AM, Soliman OI, Geleijnse ML, Nemes A, Vletter WB, ten Cate JM. Assessment of left atrial volume and function by real-time three-dimensional echocardiography. *Int J Cardiol* 2008; 123: 155–61.

46 Muller H, Burri H, Shah D, Lerch R. Evaluation of left atrial size in patients with atrial arrhythmias: comparison of standard 2D versus real time 3D echocardiography. *Echocardiography* 2007; 24: 960–66.

47 Sub IW, Song JM, Lee EY, Kang SH, Kim MJ, Kim JJ, *et al*. Left atrial volume measured by real-time 3-dimensional echocardiography predicts clinical outcomes in patients with severe left ventricular dysfunction and in sinus rhythm. *J Am Soc Echocardiogr* 2008; 21: 439–45.

48 Miyasaka Y, Tsujimoto S, Maeba H, Yuasa F, Takehana K, Dote K, *et al*. Left atrial volume by real-time three-dimensional echocardiography: validation by 64-slice multidetector computed tomography. *J Am Soc Echocardiogr* 2011; 24: 680–86.

49 Delgado V, Vidal B, Stiges M, Tamborero D, Mont L, Berruezo A, *et al*. Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation. *Am J Cardiol* 2008; 101: 1285–90.

50 Pepi M, Tamborini G, Maltagliati A, Galli CA, Sisillo E, Salvi L, *et al*. Head-to-head comparison of two-and three-dimensional transharotic and transesophageal echocardiography in the localization of mitral valve prolapse. *J Am Coll Cardiol* 2006; 48: 2524–30.

51 Tamborini G, Muratori M, Maltagliati A, Galli CA, Naliato M, Zanobini M, *et al*. Pre-operative transharotic real-time three-dimensional echocardiography in patients undergoing mitral valve repair: accuracy in cases with simple vs. complex prolapse lesions. *Eur J Echocardiogr* 2010; 11: 778–85.

52 Grewal J, Mankad S, Freeman WK, Click RL, Suri RM, Abel MD, *et al*. Real-time three-dimensional transesophageal echocardiography in the intraoperative assessment of mitral valve disease. *J Am Soc Echocardiogr* 2009; 22: 34–41.

53 Muller S, Muller L, Laufer G, Alber H, Dichit W, Frick M, *et al*. Comparison of three-dimensional imaging to transesophageal echocardiography for preoperative evaluation in mitral valve prolapse. *Am J Cardiol* 2006; 98: 243–48.

54 Grewal J, Majdalany D, Syed I, Pelliikka P, Warnes CA. Three-dimensional echocardiographic assessment of right ventricular volume and function in adult patients with congenital heart disease: comparison with magnetic resonance imaging. *J Am Soc Echocardiogr* 2010; 23: 127–33.

55 Perez de Isla L, Casanova C, Almeria C, Rodrigo JL, Cordeiro P, Mataix L, *et al*. Which method should be the reference method to evaluate the severity of rheumatic mitral stenosis? Gorlin's method versus 3D-echo. *Eur J Echocardiogr* 2007; 8: 470–73.

56 Sugeng L, Weinert L, Lammertin G, Thomas P, Spencer KT, Decara JM, *et al*. Accuracy of mitral valve area measurements using transthoracic rapid freehand 3-dimensional scanning: comparison with noninvasive and invasive methods. *J Am Soc Echocardiogr* 2003; 16: 1292–300.

57 Zamorano J, Perez de Isla L, Sugeng L, Cordeiro P, Rodrigo JL, Almeria C, *et al*. Non-invasive assessment of mitral valve area during percutaneous balloon mitral valvuloplasty: role of real-time 3D echocardiography. *Eur Heart J* 2004; 25: 2086–91.

58 Zamorano J, Cordeiro P, Sugeng L, Perez de Isla L, Weinert L, Macaya C, *et al*. Real-time three-dimensional echocardiography for rheumatic mitral valve stenosis evaluation: an accurate and novel approach. *J Am Coll Cardiol* 2004; 43: 2091–96.

59 Binder TM, Rosenhek R, Porenta G, Maurer G, Baumgartner H. Improved assessment of mitral valve stenosis by volumetric real-time three-dimensional echocardiography. *J Am Coll Cardiol* 2000; 36: 1355–61.

60 Mannaerts HF, Kamp O, Visser CA. Should mitral valve area assessment in patients with mitral stenosis be based on anatomical or on functional evaluation? A plea for 3D echocardiography as the new clinical standard. *Eur Heart J* 2004; 25: 2073–74.

61 Sebag IA, Morgan JG, Handschumacher MD, Marshall JE, Nesta F, Hung J, *et al.* Usefulness of three-dimensionally guided assessment of mitral stenosis using matrix-array ultrasound. *Am J Cardiol* 2005; 96: 1151–56.

62 Messika-Zeitoun D, Brochet E, Holmin C, Rosenbaum D, Cormier B, Serfaty JM, *et al*. Three-dimensional evaluation of the mitral valve area and commissural opening before and after percutaneous mitral commissurotomy in patients with mitral stenosis. *Eur Heart J* 2007; 28: 72–79.

63 Kasprzak JD, Nosir YF, Dall’Agata A, Elhendy A, Taams M, Ten Cate JM, *et al*. Quantification of the aortic valve area in three-dimensional echocardiographic data sets: analysis of orifice overestimation resulting from suboptimal cut-plane selection. *Am Heart J* 1998; 135: 995–1003.

64 Suradi H, Byers S, Green-Hess D, Gradus-Pizlo I, Sawada S, Feigenbaum H. Feasibility of using real time “Live 3D” echocardiography to visualize the stenotic aortic valve. *Echocardiography* 2010; 27: 1011–20.

65 de la Morena G, Saura D, Oliva MJ, Soria F, Gonzalez J, Garcia M, *et al*. Real-time three-dimensional transoesophageal echocardiography in the assessment of aortic valve stenosis. *Eur J Echocardiogr* 2010; 11: 9–13.

66 Nakai H, Takeuchi M, Yoshihata H, Kaku K, Haruki N, Otsuji Y. Pitfalls of anatomical aortic valve area measurements using two-dimensional transoesophageal echocardiography and the potential of three-dimensional transoesophageal echocardiography. *Eur J Echocardiogr* 2010; 11: 369–76.

67 Gutierrez-Chico JL, Zamorano JL, Prieto-Moriche E, Hernandez-Antolin RA, Bravo-Amaro M, Perez de Isla L, *et al*. Real-time three-dimensional echocardiography in aortic stenosis: a novel, simple, and reliable method to improve accuracy in area calculation. *Eur Heart J* 2008; 29: 1296–306.

68 Poh KK, Levine RA, Solis J, Shen L, Flaherty M, Kang YJ, *et al*.
al. Assessing aortic valve area in aortic stenosis by continuity equation: a novel approach using real-time three-dimensional echocardiography. *Eur Heart J* 2008; 29: 2526–35.

69 Pemberton J, Li X, Kenny A, Davies CH, Minette MS, Sahn DJ. Real-time 3-dimensional Doppler echocardiography for the assessment of stroke volume: an in vivo human study compared with standard 2-dimensional echocardiography. *J Am Soc Echocardiogr* 2005; 18: 1030–36.

70 Ge S, Bu L, Zhang H, Schelbert E, Disterhoft M, Li X, et al. A real-time 3-dimensional digital Doppler method for measurement of flow rate and volume through mitral valve in children: a validation study compared with magnetic resonance imaging. *J Am Soc Echocardiogr* 2005; 18: 1–7.

71 Sugeng L, Weinert L, Lang RM. Real-time 3-dimensional color Doppler flow of mitral and tricuspid regurgitation: feasibility and initial quantitative comparison with 2-dimensional methods. *J Am Soc Echocardiogr* 2007; 20: 1050–57.

72 Sitges M, Jones M, Shiota T, Qin JX, Tsujino H, Bauer F, et al. Real-time three-dimensional color doppler evaluation of the flow convergence zone for quantification of mitral regurgitation: Validation experimental animal study and initial clinical experience. *J Am Soc Echocardiogr* 2003; 16: 38–45.

73 Yosefy C, Levine RA, Solis J, Vaturi M, Handschumacher MD, Hung J. Proximal flow convergence region as assessed by real-time 3-dimensional echocardiography: challenging the hemispheric assumption. *J Am Soc Echocardiogr* 2007; 20: 389–96.

74 Kahler P, Plicht B, Schenk IM, Janosi RA, Erbel R, Buck T. Direct assessment of size and shape of noncircular vena contracta area in functional versus organic mitral regurgitation using real-time three-dimensional echocardiography. *J Am Soc Echocardiogr* 2008; 21: 912–21.

75 Chin CH, Chen CH, Lo HS. The correlation between three-dimensional vena contracta area and aortic regurgitation index in patients with aortic regurgitation. *Echocardiography* 2010; 27: 161–66.

76 Fang L, Hsiung MC, Miller AP, Nanda NC, Yin WH, Young MS, et al. Assessment of aortic regurgitation by live three-dimensional transesophageal echocardiographic measurements of vena contracta area: usefulness and validation. *Echocardiography* 2005; 22: 775–81.

77 Lodato JA, Cao QL, Weinert L, Sugeng L, Lopez J, Lang RM, et al. Feasibility of real-time three-dimensional transesophageal echocardiography for guidance of percutaneous atrial septal defect closure. *Eur J Echocardiogr* 2009; 10: 543–48.

78 Morgan GJ, Casey F, Craig B, Sands A. Assessing ASDs prior to device closure using 3D echocardiography. Just pretty pictures or a useful clinical tool? *Eur J Echocardiogr* 2008; 9: 478–82.

79 van den Bosch AE, Ten Harkel DJ, McGhie JS, Reos-Hesselink JW, Simoons ML, Bogers AJ, et al. Characterization of atrial septal defect assessed by real-time 3-dimensional echocardiography. *J Am Soc Echocardiogr* 2006; 19: 815–21.

80 Acar P, Abdur R, Argoun Y. Transcatheter closure of perimembranous ventricular septal defects with Amplatzer occluder assessed by real-time three-dimensional echocardiography. *Eur J Echocardiogr* 2007; 8: 110–15.

81 Daimon M, Gillinov AM, Liddicoat JR, Saracino G, Fukuda S, Koyama Y, et al. Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography. *J Am Soc Echocardiogr* 2007; 20: 381–88.

82 Garcia-Fernandez MA, Cortes M, Garcia-Robles JA, Gomez de Diego JJ, Perez-David E, Garcia E. Utility of real-time three-dimensional transeosophageal echocardiography in evaluating the success of percutaneous transcatheter closure of mitral paravalvular leaks. *J Am Soc Echocardiogr* 2010; 23: 26–32.

83 Becerra JM, Almeria C, de Isla LP, Zamorano J. Usefulness of 3D transeosophageal echocardiography for guiding wires and closure devices in mitral perivalvular leaks. *Eur J Echocardiogr* 2009; 10: 979–81.

84 Kim MS, Casserly IP, Garcia JA, Klein Al, Salcedo EE, Carroll JD. Percutaneous transcatheter closure of prosthetic mitral paravalvular leaks: are we there yet? *JACC Cardiovasc Interv* 2009; 2: 81–90.

85 Tsang W, Lang RM, Kronzon I. Role of real-time three-dimensional echocardiography in cardiovascular interventions. *Heart* 2011; 97: 850–57.

86 Shah SJ, Barro DM, Sugeng L, Weinert L, Lodato JA, Knight BP, et al. Real-time three-dimensional transeosophageal echocardiography of the left atrial appendage: initial experience in the clinical setting. *J Am Soc Echocardiogr* 2008; 21: 1362–68.

87 Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. and the American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. *J Am Soc Echocardiogr* 2008; 21: 1179–201, quiz 1281.

88 Lester SJ, Miller FA Jr, Khandheria BK. Contrast echocardiography: beyond a black box warning? *J Am Soc Echocardiogr* 2008; 21: 417–18.

89 Kusznetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. *J Am Coll Cardiol* 2008; 51: 1704–06.

90 Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottiendeier JS, Hausenrover E, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. *J Am Coll Cardiol* 1998; 32: 746–52.

91 Crouse LJ, Cheirif J, Hanly DE, Kissolo JA, Labovitz AJ, Raichlen JS, et al. Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography: results of the Phase III Albunex Multicenter Trial. *J Am Coll Cardiol* 1993; 22: 1494–500.

92 Lindner JR, Dent JM, Moos SP, Jayaweera AR, Kaul S. Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex. *Am J Cardiol* 1997; 79: 1657–62.

93 Allen MR, Pellicka PA, Villarraga HR, Klarich KW, Foley DA, Mulvagh SL, et al. Harmonic imaging: echocardiographic enhanced contrast intensity and duration. *Int J Card Imaging* 1999; 15: 215–20.

94 Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottfried JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. *Am J Cardiol* 2000; 86: 669–74.

95 Dolan MS, Riad K, El-Shafei A, Puri S, Tamirisa K, Bierig M, et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. *Am Heart J* 2001; 142: 908–15.

96 Rainbird AJ, Mulvagh SL, Oh JK, McCully RB, Klarich KW, Shub C, et al. Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients. *J Am Soc Echocardiogr* 2001; 14: 378–85.

97 Plana JC, Mikati IA, Dokainish H, Lakks N, Abukhalil J, Davis R, et al. A randomized cross-over study for evaluation of the effect of image optimization with contrast on the diagnostic accuracy of dobutamine echocardiography in coronary artery disease.
110 Gorescn J 3rd, Kanzaki H, Bazaz R, Dohi K, Schwartzman D. Usefulness of echocardiographic tissue synchronization imaging to predict acute myocardial ischemia: active contraction or passive recoil? Circulation 2002; 107: 1188–92.

111 Yu CM, Gorescn J 3rd, Bleeker GB, Zhang Q, Schalij MJ, Suffoletto MS, et al. Usefulness of tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002; 106: 718–24.

112 Perry R, De Pasquale CG, Chew DP, Aylward PE, Joseph MX. QRS duration alone misses cardiac dyssynchrony in a substantial proportion of patients with chronic heart failure. J Am Soc Echocardiogr 2006; 19: 483–88.

113 Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608–16.

114 Suffoletto MS, Dohi K, Cannesson M, Saba S, Gorcsan J 3rd. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006; 113: 960–68.

115 Gorcsan J 3rd, Tanabe M, Bleeker GB, Suffoletto MS, Thomas NC, Saba S, et al. Combined longitudinal and radial dyssynchrony predicts ventricular response after resynchronization therapy. J Am Coll Cardiol 2007; 50: 1476–83.

116 Lim P, Buakhammsri A, Popovic ZB, Greenberg NL, Patel D, Thomas JD, et al. Longitudinal strain delay index by speckle tracking imaging: a new marker of response to cardiac resynchronization therapy. Circulation 2008; 118: 1130–37.

117 Tanaka H, Nesser HJ, Buck T, Oyenuga O, Janosi RA, Winter S, et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. Eur Heart J 2010; 31: 1690–700.

118 D’Hooge J, Heimdal A, Jamal F, Kukulski T, Bijens B, Rademakers F, et al. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 2000; 1: 154–70.

119 Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol 2006; 47: 789–93.

120 Becker M, Blik E, Kuhl H, Kato M, Kramann R, Franke A, et al. Analysis of myocardial deformation based on pixel tracking in two-dimensional echocardiographic images enables quantitative assessment of regional left ventricular function. Heart 2006; 92: 1102–08.

121 Langeland S, D’Hooge J, Wouters PF, Leather HA, Claus P, Bijnens B, et al. Experimental validation of a novel ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insolation angle. Circulation 2005; 112: 2157–62.

122 Toyoda T, Baba H, Akasaka T, Akiyama M, Neishi Y, Tomita J, et al. Assessment of regional myocardial strain by a novel automated tracking system from digital image files. J Am Soc Echocardiogr 2004; 17: 1234–38.

123 Bijens B, Claus P, Weidemann F, Strømstø J, Sutherland GR. Investigating cardiac function using motion and deformation analysis in the setting of coronary artery disease. Circulation 2007; 116: 2453–64.

124 Edvardsen T, Aakhus S, Endresen K, Bjørnerheim R, Smiseth OA, Ihlen H. Acute regional myocardial ischemia identified by 2-dimensional multiregion tissue Doppler imaging technique. J Am Coll Cardiol 2004; 44: 1834–40.

125 Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 2002; 106: 50–56.

126 Urheim S, Edvardsen T, Steine K, Skulstad H, Lyseggen E, Rodevand O, et al. Postystolic shortening of ischemic myocardium: a mechanism of abnormal intraventricular filling. Am J Physiol Heart Circ Physiol 2003; 284: H2343–50.

127 Weidemann F, Dommek C, Bijens B, Claus P, D’Hooge J, Merten P, et al. Defining the transmurality of a chronic myocardial infarction by ultrasonic strain-rate imaging: implications for identifying intramural viability: an experimental study. Circulation 2003; 107: 883–88.
128 Roes SD, Kelle S, Kaandorp TA, Kokocinski T, Poldermans D, Lamb HJ, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. *Am J Cardiol* 2007; 100: 930–36.

129 Roes SD, Mollema SA, Lamb HJ, van der Wall EE, de Roos A, Bax JJ. Validation of echocardiographic two-dimensional speckle tracking longitudinal strain imaging for viability assessment in patients with chronic ischemic left ventricular dysfunction and comparison with contrast-enhanced magnetic resonance imaging. *Am J Cardiol* 2009; 104: 312–17.

130 Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2006; 47: 1175–81.

131 Palka P, Lange A, Fleming AD, Donnelly JE, Dutka DP, Starkey IR, et al. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. *J Am Coll Cardiol* 1997; 30: 760–68.

132 Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. *Circulation* 2004; 110: 3808–14.

133 Yang H, Sun JP, Lever HM, Popovic ZB, Drinko JK, Greenberg NL, et al. Use of strain imaging in detecting segmental dysfunction in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2003; 16: 233–39.

134 Yajima R, Kataoka A, Takahashi A, Uehara M, Saito M, Yamaguchi C, et al. Distinguishing focal fibrotic lesions and non-fibrotic lesions in hypertrophic cardiomyopathy by assessment of regional myocardial strain using two-dimensional speckle tracking echocardiography: Comparison with multislice CT. *Int J Cardiol* 2011.

135 Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispensieri A, Oh JK, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. *J Am Soc Echocardiogr* 2007; 20: 1194–202.

136 Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. *Eur J Echocardiogr* 2006; 7: 22–30.

137 Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. *Circulation* 2003; 107: 2446–52.

138 Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. *JACC Cardiovasc Imaging* 2010; 3: 333–42.

139 Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. *Heart* 2010; 96: 701–07.

140 Onishi T, Kawai H, Tatsumi K, Kataoka T, Sugiyama D, Tanaka H, et al. Preoperative systolic strain rate predicts postoperative left ventricular dysfunction in patients with chronic aortic regurgitation. *Circ Cardiovasc Imaging* 2010; 3: 134–41.

141 Delgado V, Tops LF, van Bommel RJ, van der Kley F, Marsan NA, Klautz RJ, et al. Strain analysis in patients with severe aortic stenosis and preserved left ventricular ejection fraction undergoing surgical valve replacement. *Eur Heart J* 2009; 30: 3037–47.

142 de Isla LP, de Agustin A, Rodrigo JL, Almeria C, del Carmen Manzano M, Rodriguez E, et al. Chronic mitral regurgitation: a pilot study to assess preoperative left ventricular contractile function using speckle-tracking echocardiography. *J Am Soc Echocardiogr* 2009; 22: 831–38.

143 Tayyareci Y, Yildirimturk O, Aytekin V, Demiroglu IC, Aytekin S. Subclinical left ventricular dysfunction in asymptomatic severe aortic regurgitation patients with normal ejection fraction: a combined tissue Doppler and velocity vector imaging study. *Echocardiography* 2010; 27: 260–68.

144 Camell M, Lisi M, Giacomini E, Caputo M, Navarri R, Malandrino A, et al. Chronic mitral regurgitation: left atrial deformation analysis by two-dimensional speckle tracking echocardiography. *Echocardiography* 2011; 28: 327–34.

145 Mizariene V, Bucyty S, Zaliaduonyte-Peksiene D, Jonkaitiene R, Vaskelyte J, Jurkevicius R. Left ventricular mechanics in asymptomatic normotensive and hypertensive patients with aortic regurgitation. *J Am Soc Echocardiogr* 2011; 24: 385–91.

146 Donal E, Thebault C, O’Connor K, Veillard D, Rosca M, Pierard L, et al. Impact of aortic stenosis on longitudinal myocardial deformation during exercise. *Eur J Echocardiogr* 2011; 12: 235–41.